A Trial of Baricitinib in Patients With Cardiac Sarcoidosis

Key Inclusion Criteria: * Diagnosis of cardiac sarcoidosis based on one of the following pathways: * Histological Diagnosis * Myocardial or extracardiac biopsy demonstrating non-caseating granuloma with no alternative cause identified AND * Abnormal FDG uptake on cardiac PET-CT conducted within six weeks of Screening, in a pattern consistent with active cardiac sarcoidosis AND * Exclusion of other causes for cardiac manifestations * Clinical Diagnosis * One or more of the following is present: * Steroid +/- immunosuppressant responsive cardiomyopathy or heart block * Unexplained reduced LVEF (\< 40%) and/or segmental wall motion abnormalities not related to coronary artery disease or another defined cause * Unexplained sustained (spontaneous or induced) VT * Mobitz type II 2nd degree heart block or 3rd degree heart block * CT chest and/or FDG PET-CT showing features consistent with pulmonary sarcoidosis and/or hilar lymphadenopathy AND * Abnormal FDG uptake on cardiac PET-CT conducted within 6 weeks of Screening, in a pattern consistent with active cardiac sarcoidosis AND * Exclusion of other causes for cardiac manifestations * Active cardiac sarcoidosis based on abnormal FDG uptake on cardiac PET-CT conducted within six weeks of Screening, in a pattern consistent with active cardiac sarcoidosis * No current treatment with immunosuppressive medications other than a steroid-sparing medication (including methotrexat…